Favorable Nonclinical Safety Profile of RSVpreF Bivalent Vaccine in Rats and Rabbits.

ABSTRACT: Background: Respiratory syncytial virus (RSV) infections usually cause mild, cold-like symptoms in most people, but are a leading infectious disease causing infant death and hospitalization and can result in increased morbidity and mortality in older adults and at-risk individuals. Pfizer has developed Abrysvo^®, an unadjuvanted bivalent recombinant protein subunit vaccine containing prefusion-stabilized fusion (F) proteins representing RSV A and RSV B subgroups (RSVpreF). It is the only RSV vaccine approved for both maternal immunization to protect infants and active immunization of older adults (≥60 years) and 18-59-year-old individuals with high-risk conditions for prevention of RSV disease. Methods: Nonclinical safety studies, including a repeat-dose toxicity (R

SUBMITTER: Zhou J 

PROVIDER: S-EPMC11769190 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature